Skip to content

Removing-Dampness Method for Treatment of Moderate Plaque Psoriasis: an Exploratory Clinical Trial

Removing-Dampness Method for Treatment of Moderate Plaque Psoriasis: an Exploratory Clinical Trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003389
Enrollment
Unknown
Registered
2020-06-10
Start date
2020-06-08
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis

Interventions

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 70 years, not restrictions on male or female; 2. Patients who meet the diagnostic criteria of stable plaque psoriasis; 3. 3 <= PASI < 10; 4. Fill in the syndrome diagnostic criteria of dampness syndrome and non-dampness syndrome; 5. Informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnancy, breastfeeding women, or a planned pregnancy within one year; 2. Vulgaris psoriasis patients with severe primary diseases involving respiratory system, circulatory system, digestive system, endocrine system and urinary system, etc., which can not be controlled by comment medicine.Vulgaris psoriasis patients with severe infection, hepatitis, tuberculosis, lymphocytic hyperplasia, abnormal hematopoietic system and tumor.Vulgaris psoriasis patients with severe water, electrolyte and acid-base balance disorders.Vulgaris psoriasis patients with primary or secondary immunodeficiency and hypersensitivity.Or the clinical test index is one of the following: the ALT or the AST is higher than 1.5 times the normal value limit; the creatinine (Cr) is higher than 1.5 times the normal value limit; Hemoglobin increase > 20g/L upper limit of normal value; Decreased platelet count by 5.5mmol/L or decreased by < 3mmol/L; or patients with other abnormal laboratory tests that the researchers judged unfit to participate in the trial; 3. They are known to be allergic to drugs used in the study and those who are allergic to the drugs involved. 4. Participants in other clinical trials or other clinical trials in 1 month; 5. Patients who the researchers consider are not suitable for inclusion.

Design outcomes

Primary

MeasureTime frame
The proportion of patients who achieve at least 75% improvement in PASI score from baseline;

Secondary

MeasureTime frame
Subject satisfaction;Average decrease of Skindex16 score;Improvement of Pruritus Scores on the Visual Analogue Scale;Average decrease of VAS score;The average score of the Main Symptom scale for Psoriasis Vulgaris decreased;Medication compliance;Average decrease of Dermatology Life Quality Index (DLQI) score;Improvement of Body Surface Area;Average decrease of Physician's global assessment (PGA) score;The improvement in PASI score from baseline after treatment;

Countries

China

Contacts

Public ContactYuhong Yan

Guangdong Provincial Hospital of Chinese Medicine

15920395608@139.com+86 15920395608

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026